Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Blood Disorders Therapeutics Market to 2017The report provides in-depth analysis of the drivers and barriers that impact the global blood disorders market.
By: Rajesh Gunnam • Annualized market data for the blood disorders market from 2002 to 2010, forecast forward to 2017. • Analysis of the leading therapeutic segments, including anemia, thrombosis, neutropenia, hemophilia A, hemophilia B, hemophilia C, von Willebrand’s disease and Alexander’s disease. • Analysis of the blood disorders market in the leading geographic regions of the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. • Market characterization of the blood disorders market, including market size, annual cost of treatment and treatment usage patterns. For Sample Pages, please click or add the below link to your browser: http://www.gbiresearch.com/ GBI Research, the leading business intelligence provider, has released its latest research, “Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth”. The report provides in-depth analysis of the drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographic regions as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The global blood disorders market is rapidly growing due to the growing anemia, hemophilia A, hemophilia B and vWD populations in the developed countries, as well as the increasing cost of treating blood disorders with the introduction of new, improved and costly biologics and recombinant products in the anemia, neutropenia, hemophilia A, hemophilia B and Alexander’s disease markets. Additionally, the approval of Alphanate and Humate-P/Haemate- The thrombosis market, with sales worth $14.4 billion in 2010, accounts for 36.6% of the total blood disorders market. The anemia market is estimated to be worth $12.5 billion, the second largest blood disorders market, and to have grown at a CAGR of 9.3% between 2002 and 2010. While the neutropenia market registered a market share of 17.1% in 2010, the hemophilia A, hemophilia B, hemophiliac, Alexander’s disease and von Willebrand’s Disease (vWD) markets registered shares approximately of 6%, 2.6%, 0.01%, 0.6% and 0.4%, respectively, of the global blood disorders market. A rapid increase in the global hemophilia A population, particularly in the US, the UK, Germany and France, has led to growth in the hemophilia A market. In addition, high growth in the annual cost of treating blood disorders, particularly anemia, hemophilia A and hemophilia B, has led to growth in the blood disorders market. A rapid increase in the global anemic population, particularly in the UK, has led the growth of the anemia market. Plavix, co-marketed by Sanofi- Aventis and BMS (Bristol-Myers Squibb), is the leading drug in the blood disorders market, with combined sales worth more than $8.7 billion in 2010, followed by Neulasta, manufactured by Amgen, with sales of $4.8 billion in 2010. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/ Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number